BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma

Journal of Cutaneous Pathology

Volumn 39, Issue 9, 2012, Pages 821-825

  Kim, Jinhyun ^a   Lazar, Alexander J ^a   Davies, Michael A ^a   Homsi, Jade ^a   Papadopoulos, Nicholas E ^a   Hwu, Wen Jen ^a   Bedikian, Agop Y ^a   Woodman, Scott E ^a   Patel, Sapna P ^a   Hwu, Patrick ^a   Kim, Kevin B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BRAF; KIT; melanoma; NRAS; spindle cell

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN P21; STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; GENETICS; HEAD AND NECK TUMOR; HUMAN; MALE; MELANOMA; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 84865400526     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2012.01950.x     Document Type: Article

References (23)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK,. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20.
2. Siegel R, Ward E, Brawley O, Jemal A,. Cancer Statistics, 2011. CA Cancer J Clin 2011; 61: 212.
3. Langley RG, Sober AJ,. Clinical recognition of melanoma and its precursors. Hematol Oncol Clin North Am 1998; 12: 699, v.
4. Weinstock MA, Sober AJ,. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303.
5. Reintgen DS, McCarty KM Jr, Cox E, Seigler HF,. Malignant melanoma in black American and white American populations. A comparative review. JAMA 1982; 248: 1856.
6. Bruijn JA, Mihm MC Jr, Barnhill RL,. Desmoplastic melanoma. Histopathology 1992; 20: 197.
7. Sangueza OP, Requena L,. Neoplasms with neural differentiation: a review. Part II: malignant neoplasms. Am J Dermatopathol 1998; 20: 89.
8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949.
9. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340.
10. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135.
11. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG,. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126: 154.
12. Goydos JS, Mann B, Kim HJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200: 362.
13. Lee JH, Choi JW, Kim YS,. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2010; 164: 776.
14. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327.
15. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046.
16. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28 (Suppl; abstr 8503): 15s.
17. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507.
18. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707.
19. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809.
20. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103: 788.
21. Jain S, Allen PW,. Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol 1989; 13: 358.
22. Ahmadian A, Ehn M, Hober S,. Pyrosequencing: history, biochemistry and future. Clin Chim Acta 2006; 363: 83.
23. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010; 12: 425.